Brief: Nls Pharmaceutics AG - Announces Patent Issuance In The United States For Its Mazindol Extended-Release Formulation
04/01/2022 13:16
Jan 4 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS AG - ANNOUNCES PATENT ISSUANCE IN THE
UNITED
STATES FOR ITS MAZINDOL EXTENDED-RELEASE FORMULATION
* NLS PHARMACEUTICS AG - KEY PATENT NOW GRANTED IN MARKETS
INCLUDING THE U.S., EUROPE, CANADA & SOUTH KOREA
* NLS PHARMACEUTICS AG - PATENT CLAIMS COVER USE OF CO'S
LEAD
PRODUCT CANDIDATE, QUILIENCE (MAZINDOL ER) IN ADHD & NARCOLEPSY
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing